Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021

Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021. Oncology Fact Sheet Nr. 53.

[thumbnail of Oncology Fact Sheet Nr.53_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
96kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WR Dermatology
Language:	English
Series Name:	Oncology Fact Sheet Nr. 53
Deposited on:	28 Jun 2021 14:10
Last Modified:	15 Sep 2021 14:30

Repository Staff Only: item control page